Norman Eansor

B-MoGen Biotechnologies, Inc. provides gene editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing. It offers custom vector generation services that include multi-gene expression vectors that are delivered via the proven sleeping beauty transposon system; and custom gene targeting vectors. The company was founded by David A. Largaespada and Branden S. Moriarity in 2015 and is headquartered in Minneapolis, MN.

B-MoGen Biotechnologies, Inc. provides gene editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing. It offers custom vector generation services that include multi-gene expression vectors that are delivered via the proven sleeping beauty transposon system; and custom gene targeting vectors. The company was founded by David A. Largaespada and Branden S. Moriarity in 2015 and is headquartered in Minneapolis, MN.

B-MoGen Biotechnologies, Inc. provides gene editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing. It offers custom vector generation services that include multi-gene expression vectors that are delivered via the proven sleeping beauty transposon system; and custom gene targeting vectors. The company was founded by David A. Largaespada and Branden S. Moriarity in 2015 and is headquartered in Minneapolis, MN.

CyVek, Inc. engages in the development of a novel, platform technology for measuring analytes in biological samples. It is a biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays. The firm is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings. The company offers an breadth of applications, from life science research to drug discovery, personalized medicine, diagnostics, and point-of-care testing. CyVek was founded by Per J. Hellsund, Rajiv Pandey and Marty Andrew Putnam in 2010 and is headquartered in Wallingford, CT.

CyVek, Inc. engages in the development of a novel, platform technology for measuring analytes in biological samples. It is a biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays. The firm is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings. The company offers an breadth of applications, from life science research to drug discovery, personalized medicine, diagnostics, and point-of-care testing. CyVek was founded by Per J. Hellsund, Rajiv Pandey and Marty Andrew Putnam in 2010 and is headquartered in Wallingford, CT.

CyVek, Inc. engages in the development of a novel, platform technology for measuring analytes in biological samples. It is a biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays. The firm is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings. The company offers an breadth of applications, from life science research to drug discovery, personalized medicine, diagnostics, and point-of-care testing. CyVek was founded by Per J. Hellsund, Rajiv Pandey and Marty Andrew Putnam in 2010 and is headquartered in Wallingford, CT.

B-MoGen Biotechnologies, Inc. provides gene editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing. It offers custom vector generation services that include multi-gene expression vectors that are delivered via the proven sleeping beauty transposon system; and custom gene targeting vectors. The company was founded by David A. Largaespada and Branden S. Moriarity in 2015 and is headquartered in Minneapolis, MN.

CyVek, Inc. engages in the development of a novel, platform technology for measuring analytes in biological samples. It is a biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays. The firm is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings. The company offers an breadth of applications, from life science research to drug discovery, personalized medicine, diagnostics, and point-of-care testing. CyVek was founded by Per J. Hellsund, Rajiv Pandey and Marty Andrew Putnam in 2010 and is headquartered in Wallingford, CT.

B-MoGen Biotechnologies, Inc. provides gene editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing. It offers custom vector generation services that include multi-gene expression vectors that are delivered via the proven sleeping beauty transposon system; and custom gene targeting vectors. The company was founded by David A. Largaespada and Branden S. Moriarity in 2015 and is headquartered in Minneapolis, MN.